The Risk of Missed Gastroesophageal Cancer Diagnoses in Users and Nonusers of Antisecretory Medication  Annmarie Lassen, Jesper Hallas, Ove B. Schaffalitzky de Muckadell  Gastroenterology  Volume 129, Issue 4, Pages 1179-1186 (October 2005) DOI: 10.1053/j.gastro.2005.07.028 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Expected time to diagnosis of gastroesophageal cancer in patients undergoing endoscopy for the first time with and without redeemed prescriptions for antisecretory medication in the past 180 days. *Adjusted for sex and age group (<50 years, 50–69 years, and ≥ 70 years) by Cox regression modeling. Baseline survivor function for male patients aged 50–69 years at their first endoscopy. Gastroenterology 2005 129, 1179-1186DOI: (10.1053/j.gastro.2005.07.028) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Mortality in the cohort of all patients diagnosed with gastroesophageal cancer (n = 513). *Adjusted for sex and age group (<50 years, 50–69 years, and ≥ 70 years) by Cox regression analysis. Baseline survivor function for male patients aged 50–69 years at their first endoscopy. Gastroenterology 2005 129, 1179-1186DOI: (10.1053/j.gastro.2005.07.028) Copyright © 2005 American Gastroenterological Association Terms and Conditions